These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37871407)

  • 1. An updated review of chemical compounds with anti-Toxoplasma gondii activity.
    Rodriguez JB; Szajnman SH
    Eur J Med Chem; 2023 Dec; 262():115885. PubMed ID: 37871407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New antibacterials for the treatment of toxoplasmosis; a patent review.
    Rodriguez JB; Szajnman SH
    Expert Opin Ther Pat; 2012 Mar; 22(3):311-33. PubMed ID: 22404108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Heptaprenyl Diphosphate Synthase (Coq1) Is the Target of a Lipophilic Bisphosphonate That Protects Mice against Toxoplasma gondii Infection.
    Sleda MA; Li ZH; Behera R; Baierna B; Li C; Jumpathong J; Malwal SR; Kawamukai M; Oldfield E; Moreno SNJ
    mBio; 2022 Oct; 13(5):e0196622. PubMed ID: 36129297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapeutics for
    Wu RZ; Zhou HY; Song JF; Xia QH; Hu W; Mou XD; Li X
    J Med Chem; 2021 Dec; 64(24):17627-17655. PubMed ID: 34894691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationships of
    Alday PH; Nilsen A; Doggett JS
    Expert Opin Drug Discov; 2022 Sep; 17(9):997-1011. PubMed ID: 35772172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic Activity between Statins and Bisphosphonates against Acute Experimental Toxoplasmosis.
    Li ZH; Li C; Szajnman SH; Rodriguez JB; Moreno SNJ
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activities of anti-Toxoplasma drugs and compounds against tissue cysts in the last three decades (1987 to 2017), a systematic review.
    Montazeri M; Mehrzadi S; Sharif M; Sarvi S; Shahdin S; Daryani A
    Parasitol Res; 2018 Oct; 117(10):3045-3057. PubMed ID: 30088074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity.
    Neville AJ; Zach SJ; Wang X; Larson JJ; Judge AK; Davis LA; Vennerstrom JL; Davis PH
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7161-9. PubMed ID: 26392504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of an in vitro system to study the developmental stages of Toxoplasma gondii using a genetically modified strain expressing markers for tachyzoites and bradyzoites.
    Portes JA; De Souza W
    Parasitol Res; 2019 Dec; 118(12):3479-3489. PubMed ID: 31728720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The High Potency of Green Synthesized Copper Nanoparticles to Prevent the Toxoplasma gondii Infection in Mice.
    Albalawi AE; Alanazi AD; Alyousif MS; Sepahvand A; Ebrahimi K; Niazi M; Mahmoudvand H
    Acta Parasitol; 2021 Dec; 66(4):1472-1479. PubMed ID: 34050875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for small molecule inhibitors of Toxoplasma gondii.
    Kortagere S
    Expert Opin Drug Discov; 2012 Dec; 7(12):1193-206. PubMed ID: 22998671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxoplasma gondii relies on both host and parasite isoprenoids and can be rendered sensitive to atorvastatin.
    Li ZH; Ramakrishnan S; Striepen B; Moreno SN
    PLoS Pathog; 2013; 9(10):e1003665. PubMed ID: 24146616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Structure-Activity Analysis of Endochin-like Quinolones Reveals Potent Qi and Qo Site Inhibitors of Toxoplasma gondii and Plasmodium falciparum Cytochrome bc
    McConnell EV; Bruzual I; Pou S; Winter R; Dodean RA; Smilkstein MJ; Krollenbrock A; Nilsen A; Zakharov LN; Riscoe MK; Doggett JS
    ACS Infect Dis; 2018 Nov; 4(11):1574-1584. PubMed ID: 30117728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phytoecdysteroids as modulators of the Toxoplasma gondii growth rate in human and mouse cells.
    Dzitko K; Grzybowski MM; Pawełczyk J; Dziadek B; Gatkowska J; Stączek P; Długońska H
    Parasit Vectors; 2015 Aug; 8():422. PubMed ID: 26272689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of lumefantrine as an effective drug against
    Wang D; Xing M; El-Ashram S; Ding Y; Zhang X; Sang X; Feng Y; Chen R; Wang X; Jiang N; Chen Q; Yang N
    Parasitology; 2021 Jan; 148(1):122-128. PubMed ID: 33087183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenosine metabolism in Toxoplasma gondii: potential targets for chemotherapy.
    el Kouni MH
    Curr Pharm Des; 2007; 13(6):581-97. PubMed ID: 17346176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of human toxoplasmosis.
    Smith NC; Goulart C; Hayward JA; Kupz A; Miller CM; van Dooren GG
    Int J Parasitol; 2021 Feb; 51(2-3):95-121. PubMed ID: 33347832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxamate-based compounds are potent inhibitors of
    Boissavy T; Rotili D; Mouveaux T; Roger E; Aliouat EM; Pierrot C; Valente S; Mai A; Gissot M
    Antimicrob Agents Chemother; 2023 Nov; 67(11):e0066123. PubMed ID: 37850734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxoplasmosis in pregnancy: prevention, screening, and treatment.
    Paquet C; Yudin MH;
    J Obstet Gynaecol Can; 2013 Jan; 35(1):78-81. PubMed ID: 23343802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dichloroacetate and Pyruvate Metabolism: Pyruvate Dehydrogenase Kinases as Targets Worth Investigating for Effective Therapy of Toxoplasmosis.
    Ferrarini MG; Nisimura LM; Girard RMBM; Alencar MB; Fragoso MSI; Araújo-Silva CA; Veiga AA; Abud APR; Nardelli SC; Vommaro RC; Silber AM; France-Sagot M; Ávila AR
    mSphere; 2021 Jan; 6(1):. PubMed ID: 33408226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.